Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a chest radiograph or computed tomography scan of the thorax (within 5 years of Screening and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other lung disease~* Has chronic cough (defined as duration of \>8 weeks after onset of cough symptoms) for ≥12 months~* Has a diagnosis of refractory chronic cough or unexplained chronic cough~* Has symptoms of SUI, defined as involuntary loss of urine on effort, physical exertion, or on sneezing or coughing, for ≥3 months~* Is a female who is not pregnant, not breastfeeding, not of childbearing potential, or agrees to follow contraceptive guidance~Exclusion Criteria:~* Is a current smoker~* Has given up smoking within 12 months of screening~* Is a former smoker with a smoking history greater than 20 pack-years (1 pack of 20 cigarettes per day for 20 years)~* Has a history of respiratory tract infection or recent change in pulmonary status within 4 weeks of screening~* Has a history of chronic bronchitis~* Has a history of surgery to treat SUI within 1 year of screening~* Has a history of other specialized treatments for SUI, including intravesical balloon or urethral bulking agent therapy~* Has other external incontinence device currently or within 1 month of screening~* Has a history of Grade 3 or higher pelvic organ prolapse previously documented or diagnosed on screening~* Has a neurogenic bladder~* Has a history of adult nocturnal incontinence~* Has a history of continuous urine leakage within 1 month of screening~* Has a history of interstitial cystitis~* Has a history of neurological disease or injury~* Has active or recurrent urinary tract infection~* Has a history of having a permanent urinary catheter or any urinary catheterization within 3 months of screening~* Has a history of malignancy ≤5 years prior to signing informed consent~* Is a user of recreational or illicit drugs or a recent history (within the last year) of drug or alcohol abuse~* Has a known allergy to gefapixant or its excipients~* Has donated or lost ≥1 unit (\~300 mL) of blood within 8 weeks prior to first dose of gefapixant~* Requires certain medications and/or other therapies that may impact their cough or bladder function~* Has previously received gefapixant~* Is currently participating or has participated in an interventional clinical study within 30 days of participating in this current study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gefapixant (Type: EXPERIMENTAL): Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).